Advances in Clinical Chemistry
- 1st Edition, Volume 43 - December 27, 2006
- Editor: Gregory S. Makowski
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 3 7 3 7 0 3 - 8
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 4 6 9 2 0 - 1
Volume 43 of the Advances in Clinical Chemistry series contains review articles of wide interest to clinical laboratory scientists and diagnostic adventurers. In this volume… Read more
Volume 43 of the Advances in Clinical Chemistry series contains review articles of wide interest to clinical laboratory scientists and diagnostic adventurers. In this volume, the biochemistry of bilirubin, the end-product of heme metabolism, is explored with respect to its potential beneficial role in preventing oxidative changes associated with a variety of pathological conditions, including atherosclerosis, cancer, and inflammatory, autoimmune and other degenerative diseases.
Biochemists and clinical biochemists.
- Contributors to Volume 43
- Publisher Summary
- Preface
- Publisher Summary
- The Heme Catabolic Pathway and its Protective Effects on Oxidative Stress-Mediated Diseases
- 1. Abstract
- 2 Introduction
- 3 Heme Catabolism
- 4 Heme Oxygenase
- 5 Hemodynamic and Cytoprotective Effects of Carbon Monoxide
- 6 Cytoprotective Effects of Biliverdin Reductase
- 7 Biological Effects of Bilirubin
- 8 Factors Affecting Serum Bilirubin Concentrations
- 9 Therapeutic Agents Affecting HO-1 Activity, CO, and Bilirubin Production
- 10 Conclusions
- Acknowledgment
- Cyclooxygenase-2 and Tumor Biology
- 1. Abstract
- 2 Introduction
- 3 Proposed Roles for COX-2 in Carcinogenesis
- 4 COX-2 Expression and Clinicopathological Factors
- 5 Fecal COX-2 Assay
- 6 Conclusions
- Acknowledgments
- Oligonucleotide Probes for RNA-Targeted Fluorescence In Situ Hybridization
- 1. Abstract
- 2 Introduction
- 3 Principles of Fluorescence In Situ Hybridization
- 4 Types of Probes
- 5 Applications
- 6 Conclusions
- Acknowledgments
- Activin A In Brain Injury
- 1. Abstract
- 2 Introduction
- 3 Biochemistry
- 4 Activin A After Brain Injury in Animals
- 5 Activin A and Neuroprotection: Findings from Animal Studies
- 6 Human Studies
- 7 Conclusions
- Methods for Predicting Human Drug Metabolism
- 1. Abstract
- 2 Introduction
- 3 In Vitro Techniques
- 4 High-Throughput Assays
- 5 In Vivo Predictions from In Vitro
- 6 Computational Metabolism Methods
- 7 Integration of Drug Metabolism Data and Interpretation
- 8 Newer Technologies
- 9 Conclusions
- Acknowledgments
- A Summary Analysis of Down Syndrome Markers in the Late First Trimester
- 1. Abstract
- 2 Introduction
- 3 Patients/Methods
- 4 Results
- 5 Discussion
- Acknowledgments
- Estrogen Hydroxylation in Osteoporosis
- 1. Abstract
- 2 Introduction
- 3 Pathways and Products of Estrogen Metabolism
- 4 Factors Influencing Estrogen Hydroxylation
- 5 Role of Estrogen Hydroxylation in Bone Density and Osteoporosis
- 6 Summary
- Acknowledgments
- Cytochrome P450: Another Player in the Myocardial Infarction Game?
- 1. Abstract
- 2 Introduction
- 3 Cytochrome P450 Enzymes
- 4 Regulation of CYP Enzyme Activity
- 5 CYP Gene Variants Interacting with Vascular Homeostasis
- 6 CYP Enzymes and Environmental Risk Factors for Cardiovascular Disease
- 7 CYP Gene–Drug Interactions in Cardiovascular Disease
- 8 Summary
- Acknowledgments
- Index
- Publisher Summary
- Edition: 1
- Volume: 43
- Published: December 27, 2006
- Language: English
GM
Gregory S. Makowski
Dr Gregory S Makowski is a board-certified clinical chemist and fellow of the National Academy of Clinical Biochemistry. Following receipt of his PhD in Biochemistry from the University of Connecticut Storrs, he pursued post-doctoral studies at the University of Connecticut School of Medicine in Farmington that culminated in joint appointments in the School of Medicine and the Department of Laboratory Medicine at John Dempsey Hospital. He has numerous clinical and basic science publications and serves on various scientific and editorial boards. He is actively engaged in the training of Pathology residents and fellows in the Department of Pathology and Laboratory Medicine at Hartford Hospital. He currently serves as Vice President Clinical Laboratory Services Hartford HealthCare in Connecticut.
Affiliations and expertise
Vice President and Chief Scientific Officer, Clinical Laboratory Partners, Newington, CT, USARead Advances in Clinical Chemistry on ScienceDirect